Standout Papers

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis 2017 2026 2020 2023 382
  1. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis (2017)
    Kim Papp, Andrew Blauvelt et al. New England Journal of Medicine

Immediate Impact

1 from Science/Nature 74 standout
Sub-graph 1 of 19

Citing Papers

Active biointegrated living electronics for managing inflammation
2024 StandoutScience
Ulcerative colitis
2023 Standout
2 intermediate papers

Works of Nathan Bennett being referenced

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
2017 Standout

Author Peers

Author Last Decade Papers Cites
Nathan Bennett 108 253 167 341 219 20 1.1k
Winston Sequeira 41 80 256 229 144 37 1.0k
Alain Le Quellec 17 96 218 234 136 35 1.1k
A. A. Drosos 76 518 237 196 124 48 1.3k
Mathilde Versini 25 151 77 283 190 17 884
G Tirri 46 75 123 260 247 42 1.3k
Maria Elena Secchi 42 100 194 250 231 18 1.3k
Bernhard H. Singsen 44 182 149 139 268 41 1.3k
P Brühlmann 79 105 208 108 132 40 1.4k
Mónica Greco 26 239 159 195 116 24 867
Christine Peloquin 62 113 225 92 143 34 1.0k

All Works

Loading papers...

Rankless by CCL
2026